Antiobesity Global Market Report 2024

“Antiobesity Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiobesity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiobesity? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The antiobesity market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Class: Peripherally acting anti obesity drugs; Centrally acting anti obesity drugs
• 2) By Type: Prescription Drugs (Rx); OTC Drugs
• 3) By Medication: Monotherapies; Polytherapies
• Companies Mentioned: F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Pfizer Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Anti-obesity drugs are pharmaceutical substances used to regulate or reduce a patient's weight. These drugs impact fundamental bodily functions related to weight control, targeting either appetite or calorie absorption. While diet and exercise remain the primary therapies for managing weight in overweight and obese individuals, anti-obesity drugs offer a supplementary option.

The key categories of anti-obesity drugs consist of peripherally acting anti-obesity medications and centrally acting anti-obesity medications. Peripherally acting anti-obesity drugs facilitate weight loss without affecting the brain or appetite. They work by inhibiting pancreatic lipase and impeding fat breakdown in the gastrointestinal tract, consequently reducing fat absorption in the intestine. These drugs are available in various forms, including prescription drugs (Rx) and over-the-counter (OTC) medications, offering both monotherapies and combination therapies to address weight management.

The anti-obesity market research report is one of a series of new reports from The Business Research Company that provides anti-obesity market statistics, including anti-obesity industry global market size, regional shares, competitors with an anti-obesity market share, detailed anti-obesity market segments, market trends and opportunities, and any further data you may need to thrive in the anti-obesity industry. This anti-obesity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiobesity market size has grown rapidly in recent years. It will grow from $3.38 billion in 2023 to $3.76 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth observed during the historical period can be attributed to several key factors, including the rising prevalence of obesity, increased awareness and education about the condition, lifestyle changes contributing to weight issues, and government initiatives aimed at addressing the obesity epidemic.

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The anticipated growth in the forecast period can be attributed to market expansion and globalization. Notable trends expected during this period include increased investment in research and development, the adoption of patient-centric approaches, expanded insurance coverage, technological advancements, the integration of digital health and telemedicine, the emergence of novel drug therapies, advancements in bariatric surgery, the availability of over-the-counter (OTC) solutions, the implementation of behavioral interventions, and the rise of nutritional and weight management apps.

Obesity is a significant global public health issue, with its prevalence increasing each year. For example, a May 2022 report from the World Obesity Atlas, a UK-based organization focused on obesity, projected that by 2030, more than 1 billion individuals worldwide are expected to be affected by obesity. This alarming trend can be attributed to the growing consumption of processed and unhealthy foods, decreased physical activity levels, and a lack of awareness regarding the risks associated with obesity. Consequently, the demand for anti-obesity drugs is poised to rise in the future, driven by the urgent need to address this global health concern and support individuals in their weight management efforts. This growing demand is expected to contribute to the expansion of the anti-obesity drug market.

The increasing geriatric population is expected to drive the growth of the anti-obesity drugs market in the future. The geriatric population encompasses older individuals, typically aged 65 and above, and obesity remains a prevalent and significant concern within this age group. Elderly individuals, especially those with diabetes, are particularly susceptible to obesity due to reduced physical activity and impaired circulation. For example, in October 2022, reports from the World Health Organization, a specialized US-based health agency, indicated that globally, one in six individuals will be 60 years or older by 2030. Furthermore, by 2050, the number of individuals in this age group is projected to double, reaching approximately 2.1 billion. Consequently, the growing geriatric population is a significant driver of the anti-obesity drugs market, as it addresses the specific needs of older individuals in managing obesity and related health issues.

Obesity is a significant global health issue driven by sedentary lifestyles and the consumption of unhealthy foods. While several anti-obesity drugs have been approved and are available in countries like the USA, European Union, Australia, and Japan to address obesity and overweight, it's important to note that these drugs may have various adverse effects on patients undergoing obesity treatment. These adverse effects can include low blood pressure, blood glucose fluctuations, incontinence, insomnia, nausea, diarrhea, and other side effects. For instance, Sibutramine and its combination drugs, sold under various brand names, were recalled in multiple countries due to various side effects, including an increased risk of heart attack in consumers. These concerns surrounding the safety and side effects of anti-obesity drugs act as a restraint on the growth of the anti-obesity drug market, as they can influence patient and healthcare provider decisions regarding treatment options.

Major companies in the anti-obesity drugs market are dedicated to innovation, with a focus on developing new products to better serve their customers. One such innovative product is Mounjaro (tirzepatide), an anti-obesity drug designed to address the needs of adults with obesity or overweight conditions, particularly those with weight-related comorbidities. For example, in October 2022, Eli Lilly and Company, a US-based pharmaceutical company, launched Mounjaro (tirzepatide), which received fast track designation approval from the Food and Drug Administration (FDA), a US-based federal agency. Mounjaro (tirzepatide) is an injectable anti-obesity drug that aims to assist individuals struggling with obesity in achieving their weight loss goals. It is indicated for use in adults with type 2 diabetes and, when combined with a diet and exercise regimen, can help improve blood sugar (glucose) control. This type of innovation demonstrates the commitment of these companies to providing effective solutions for individuals grappling with obesity and related health issues.

The pharmaceutical industry is currently experiencing a growing trend of mergers and acquisitions among companies specializing in drug development for metabolic disorders, which encompass conditions like obesity and diabetes. This strategic approach is adopted by pharmaceutical companies to bolster their drug portfolios in the field of metabolic diseases and to introduce safe and efficacious medications to the market. For example, companies like Evotec AG and Novo Nordisk have established a strategic alliance to collaborate on the discovery and development of drug molecules designed to treat metabolic disorders. These disorders include obesity, diabetes, and related health conditions. Such collaborations and partnerships represent an effort to pool resources, expertise, and innovation in the quest to bring novel and effective drugs to individuals dealing with metabolic disorders, thereby addressing a significant health challenge.

Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.

North America was the largest region in the anti-obesity market in 2023. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.